12/8/2023 0 Comments Kite pharma amsterdamThe firm says it has nearly 90 qualified treatment centers in 16 countries across Europe and Israel that will be served by the Amsterdam facility, while in the US an SEC filing in 2017 said the firm was targeting “70-90 key transplant and lymphoma centers” in the US. Meanwhile, Kite has been increasing its network of apheresis center to administer the cell therapy. Along with El Segundo and Amsterdam, construction of a facility in Frederick County, Maryland is underway with commercial production expected by late 2021, and a 67,000 square-foot facility is being built within Gilead’s site in Oceanside, California to supply viral vectors. The European site – which represents an investment of €130 million ($150 million) – is part of a focus to scale out Kite’s geographies and capabilities by owner Gilead. The Amsterdam plant will, according to Kite, have the capacity to produce therapy for up to 4,000 patients per year. The plant in El Segundo, Santa Monica opened in 2016 with capacity to treat up to 5,000 patients a year. Biotech company Kite, a part of Gilead Sciences Inc. This includes supply chain management, cryopreservation, manufacturing labs (clean rooms), quality laboratories and storage,” Kite spokesperson Nathan Kaiser told this publication. We are dedicated to achieving one of the most ambitious goals of 21st-century medicine: curing cancer. “The facility is equipped similarly to our Santa Monica facility to manufacture our cell therapy Yescarta end to end. Max van Ingen Process Engineer at Kite Pharma Den Haag. Manager, Manufacturing Technical Services at Kite Pharma, a Gilead Company Nederland. The large B-cell lymphoma treatment pulled in sales of $456 million in 2019. Word lid om profiel te bekijken Kite Pharma. Yescarta became the second CAR-T therapy to receive US FDA approval back in October 2017 and was approved by the European Commission in August 2018.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |